Trial Profile
High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Jul 2015
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2013 Planned End Date changed from 31 Jul 2012 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 11 Jul 2012 Planned end date changed from 1 Jul 2018 to 31 Jul 2012 as reported by ClinicalTrials.gov record.
- 11 Jul 2012 Additional lead trial centre, primary endpoints and actual initiation date (Jun 2012) added and planned number of patients changed from 24 to 30 as reported by ClinicalTrials.gov record.